These are the facts....I was pumping too till I realized I should I sold last week. Was expecting some sort of miracle.
MJF gave them under 500k !!! Don't think that will be enough for phase 2/3. Also with Lincoln, company will be ISSUING shares 50 million dollars...that is DILUTION.
Warrants will help but that is again DILUTION.
Same thing happened to OVAS...breaking science...stock went to 50 with all the pumps..now at 11.
This one is unfortunately broken till there is some positive news...and I don't see any news for another 2-3 months minimum. Buy in January if you still believe in the science.
I see 5 as the bottom....but no bounce expected..will still at 5+ some few days and stabilize. There is no partnership dreamers...you also know it. Way too soon for any of that.
Don't see it going below 5.
I don't need to buy it..but obviously a LOT of investors are not buying either. Did you check the stock price and volume today btw ????
ARE YOU KIDDING ME ???? I just went to the AAIC website, went to absracts, did a search, and it comes up. Come on ! IT IS THERE ! GO READ IT.
Sigma-1 Receptor Is a Molecular Target for Novel Neuroprotectant T-817MA
9:30am-4:15pm Wed, Jul 22
YOU MAY BE RIGHT...BUT NOW THIS IS SOMETHING ELSE THAT AVXL has to prove. So what they have proven so far, with the cognition improvements...just went out the window. Now they have to provide they are different than t-817MA and will not fail in a PH 2 bigger trial just like t-817MA did. Look up articles about t-817MA...even in early stages they claimed REVERSAL. Look it up.
WALL STREET does not like uncertainty. AF really messed it up. Today's results should have made PPS close at 14-15 without his article.
In that case don't expect AVXL to go anywhere above $6 (at $250M market cap) unless they come up with 2B results. But AF did a huge damage with the t-817MA comparison, especially since both are sigma-1.
If AVXL can say after 6 months results are still steller, I agree both are different class of drugs. Stock will soar then...but at 250M today, upside till then is gone.
IT HAS BEEN DISCLOSED !! Like AF said, they represented in July 2015 AICC and clearly poster said sigma -1.
You are referring to older articles.
I was long too and lost some, but got out with 200% gain today.
bump..can anyone long explain this difference ?? otherwise get off this board !!!
unless you can explain how t-817MA is different than AVXL drug (AF says both are sigma 1), your picking apart is useless. t-817MA failed with 300+ subjects.
ITS ALL ABOUT THAT TOYAMA drug t-817MA !!!! If that is really sigma-1, and it failed with 300+ n, then how is AVXL different ?? Unless longs can prove this, there is no saving AVXL.
NOTHING ELSE that AF said has any bearing on the selloff.
Someone do some digging and post how AVXL sigma-1 receptor is different than T-817MA, and this stock will go up.
Toyama presented a poster at AAIC last July. "Sigma-1 Receptor Is a Molecular Target for Novel Neuroprotectant T-817MA"
let the stock stabilize around low to mid 6...for a couple of days..no need to be a hero today. let things cool down...too many people expected $20 on Nov 9th.
 The only damaging issue from AF was the Japanese sigma-1 failed test. Someone needs to clarify if that was truly sigm-1.
 Dilution for ph 2/3. That might be coming up if they want to start it end of year.
 What is real market cap with warrants...some article mentioned 450 million...if so that is high for ph 2a.
 No news for another 2-3 months from AVXL...Bio investors (short term ones) only like to buy when there is a new term catalyst.
 TOO many bashers that have a following trashing the stock - AF, Martin, Jdallas etc. that is creating fear short term.
Look up the Japanese trial...they too mentioned 'reversing' ALZ in the initial trials...again not sure if it is the same science. If they are, I would be careful.
did search on T-817MA trials....how does AF claim this ??
Did they expect the company to announce cure of ALZ in Ph 2A, and get FDA approval on Monday ?? They showed safety and tolerance, they showed effenciency and great cognition readout. AXON and DPZ nowhere near this...P300 had 80% improvement over 'baseline' (meaning SOC DPZ).
It already corrected 40% last 2 days, stock at 250M market cap....AXON at 1.6 billion..what is not to like ?